The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Okuno SH, Frytak S

Mitomycin lung toxicity. Acute and chronic phases.

American journal of clinical oncology. 1997;20(3):282-4

Coëtmeur D, Briens E, Le Breton-Belleguic C, Bannier M, Niel-Duriez M

[Interstitial pneumonia and mitomycin C. Apropos of a case with analysis of the bronchoalveolar lavage].

Revue de pneumologie clinique. 1995;51(1):36-40

Gunstream SR, Seidenfeld JJ, Sobonya RE, McMahon LJ

Mitomycin-associated lung disease.

Cancer treatment reports. 1983;67(3):301-4

Luedke D, McLaughlin TT, Daughaday C, Luedke S, Harrison B, Reed G, Martello O

Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression.

Cancer. 1985;55(3):542-5

Gatzemeier U, Fasske E, Nowak U

[Experimental and clinical data of the pulmonary toxicity of mitomycin C].

Pneumologie (Stuttgart, Germany). 1990;44 Suppl 1:201-3

Linette DC, McGee KH, McFarland JA

Mitomycin-induced pulmonary toxicity: case report and review of the literature.

The Annals of pharmacotherapy. 1992;26(4):481-4